16P A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer

Saved in:
Bibliographic Details
Published in:ESMO open 2024-03, Vol.9, p.102595, Article 102595
Main Authors: Le, X., Elamin, Y.Y., Altan, M., Blumenschein, G., Byers, L.A., Cascone, T., Skoulidis, F., Gay, C., Tsao, A.S., Gibbons, D., Negrao, M.V., Vokes, N., Zhang, J., Heeke, S., Rotow, J., Jänne, P.A., Pellini, B., Tu, J., Gray, J.E., Heymach, J.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2059-7029
2059-7029
DOI:10.1016/j.esmoop.2024.102595